EUVIMEDEUVIMED entdecken
KorrekturOpen Access

lncRNA ASBEL and lncRNA Erbb4-IR reduce chemoresistance against gemcitabine and cisplatin in stage IV lung squamous cell carcinoma via the microRNA-21/LZTFL1 axis: Am J Cancer Res. 2023; 13(6): 2732-2750

Zong-Ying Liang, Zhi-Min Zhang, Guang-Rui Sun, Bao-Shan Zhao, Guo-Hua Xin, Le Zhang

American Journal of Cancer Research · 2026 · 16 (6) · 2677-2678

DOI: 10.62347/zzca7234 ↗

Kurz gefasst

Korrektur in der Zeitschrift American Journal of Cancer Research, 2026. Verfasst von Zong-Ying Liang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, The Affiliated Hospital of Chengde Medical University Chengde, Hebei, China. Der Volltext ist frei in PubMed Central verfügbar.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Department of Thoracic Surgery, The Affiliated Hospital of Chengde Medical University Chengde, Hebei, China.
  • Department of Education Division, The Affiliated Hospital of Chengde Medical University Chengde, Hebei, China.

Zitieren

APA

Liang, Z. Y., Zhang, Z. M., Sun, G. R., Zhao, B. S., Xin, G. H., & Zhang, L. (2026). lncRNA ASBEL and lncRNA Erbb4-IR reduce chemoresistance against gemcitabine and cisplatin in stage IV lung squamous cell carcinoma via the microRNA-21/LZTFL1 axis: Am J Cancer Res. 2023; 13(6): 2732-2750. American Journal of Cancer Research, 16(6), 2677-2678. https://doi.org/10.62347/zzca7234

Vancouver

Liang ZY, Zhang ZM, Sun GR, Zhao BS, Xin GH, Zhang L. lncRNA ASBEL and lncRNA Erbb4-IR reduce chemoresistance against gemcitabine and cisplatin in stage IV lung squamous cell carcinoma via the microRNA-21/LZTFL1 axis: Am J Cancer Res. 2023; 13(6): 2732-2750. American Journal of Cancer Research. 2026;16(6):2677-2678. doi:10.62347/zzca7234

BibTeX
@article{Liang2026,
  author = {Liang, Zong-Ying and Zhang, Zhi-Min and Sun, Guang-Rui and Zhao, Bao-Shan and Xin, Guo-Hua and Zhang, Le},
  title = {lncRNA ASBEL and lncRNA Erbb4-IR reduce chemoresistance against gemcitabine and cisplatin in stage IV lung squamous cell carcinoma via the microRNA-21/LZTFL1 axis: Am J Cancer Res. 2023; 13(6): 2732-2750},
  journal = {American Journal of Cancer Research},
  year = {2026},
  volume = {16},
  number = {6},
  pages = {2677--2678},
  doi = {10.62347/zzca7234}
}
Kostenlos starten →